Cubist Systematic Strategies’s Acceleron Pharma XLRN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q4 | – | Sell |
-1,195
| Closed | -$206K | – | 3761 |
|
|
2021
Q3 | $206K | Sell |
1,195
-12,572
| -91% | -$1.64M | ﹤0.01% | 2574 |
|
|
2021
Q2 | $1.73M | Buy |
+13,767
| New | +$1.74M | 0.02% | 1175 |
|
|
2020
Q4 | – | Sell |
-4,000
| Closed | -$450K | – | 2787 |
|
|
2020
Q3 | $450K | Sell |
4,000
-60,457
| -94% | -$6.02M | 0.01% | 1813 |
|
|
2020
Q2 | $6.14M | Buy |
64,457
+53,742
| +502% | +$5.18M | 0.11% | 249 |
|
|
2020
Q1 | $963K | Sell |
10,715
-27,828
| -72% | -$2.16M | 0.03% | 859 |
|
|
2019
Q4 | $2.04M | Buy |
38,543
+35,839
| +1,325% | +$1.63M | 0.04% | 737 |
|
|
2019
Q3 | $107K | Sell |
2,704
-13,853
| -84% | -$601K | ﹤0.01% | 1930 |
|
|
2019
Q2 | $680K | Buy |
16,557
+11,857
| +252% | +$491K | 0.01% | 1284 |
|
|
2019
Q1 | $219K | Buy |
+4,700
| New | +$206K | 0.01% | 1717 |
|
|
2018
Q4 | – | Sell |
-806
| Closed | -$46K | – | 2361 |
|
|
2018
Q3 | $46K | Sell |
806
-4,533
| -85% | -$223K | ﹤0.01% | 1720 |
|
|
2018
Q2 | $259K | Buy |
+5,339
| New | +$195K | 0.01% | 1186 |
|
|
2017
Q4 | – | Sell |
-1,506
| Closed | -$56K | – | 2169 |
|
|
2017
Q3 | $56K | Buy |
+1,506
| New | +$52.3K | ﹤0.01% | 1720 |
|
|
2017
Q2 | – | Sell |
-200
| Closed | -$5K | – | 1949 |
|
|
2017
Q1 | $5K | Buy |
+200
| New | +$5.27K | ﹤0.01% | 1583 |
|
|
2016
Q2 | – | Sell |
-19,691
| Closed | -$520K | – | 1952 |
|
|
2016
Q1 | $520K | Buy |
+19,691
| New | +$573K | 0.03% | 736 |
|
Cubist Systematic Strategies's XLRN Position: Q4 2021 in Review
Cubist Systematic Strategies sold out of Acceleron Pharma (XLRN) in Q4 2021, closing a stake of 1,195 shares — an estimated $206K sold.
Cubist Systematic Strategies first reported a position in XLRN in Q1 2016 and held it in 14 quarters. The position peaked at $6.14M in Q2 2020. 1 fund tracked by Wall St. Rank holds XLRN as of Q4 2021.
- Cubist Systematic Strategies reported no remaining Acceleron Pharma position as of Q4 2021 after selling out during the quarter.
- Cubist Systematic Strategies sold 1,195 Acceleron Pharma shares in Q4 2021, an estimated $206K.
- Cubist Systematic Strategies first reported a position in Acceleron Pharma in Q1 2016 and held it in 14 quarters.
- Cubist Systematic Strategies's Acceleron Pharma position peaked at $6.14M in Q2 2020.
- 1 fund tracked by Wall St. Rank held Acceleron Pharma as of Q4 2021.
Based on Cubist Systematic Strategies's 13F filing for Q4 2021, filed 14 Feb 2022.